Nemes Rush Group LLC Grows Stock Position in iShares Biotechnology ETF (NASDAQ:IBB)

Nemes Rush Group LLC boosted its position in iShares Biotechnology ETF (NASDAQ:IBB) by 1,464.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,430 shares of the financial services provider’s stock after purchasing an additional 6,019 shares during the quarter. Nemes Rush Group LLC’s holdings in iShares Biotechnology ETF were worth $850,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. National Bank of Canada FI lifted its stake in shares of iShares Biotechnology ETF by 5.9% in the third quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock worth $600,000 after buying an additional 229 shares in the last quarter. IFP Advisors Inc grew its position in shares of iShares Biotechnology ETF by 237.1% in the fourth quarter. IFP Advisors Inc now owns 16,018 shares of the financial services provider’s stock valued at $2,118,000 after purchasing an additional 11,266 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in iShares Biotechnology ETF during the fourth quarter worth approximately $480,000. Main Management ETF Advisors LLC boosted its stake in iShares Biotechnology ETF by 2.5% during the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after buying an additional 14,535 shares during the last quarter. Finally, Cullen Frost Bankers Inc. grew its holdings in iShares Biotechnology ETF by 1.5% in the 4th quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock valued at $748,000 after buying an additional 82 shares in the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Down 1.8 %

Shares of IBB stock opened at $127.90 on Tuesday. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57. The stock has a market cap of $6.04 billion, a price-to-earnings ratio of 27.83 and a beta of 0.84. The company’s 50-day moving average price is $136.07 and its 200-day moving average price is $138.74.

iShares Biotechnology ETF Increases Dividend

The company also recently declared a dividend, which was paid on Friday, March 21st. Stockholders of record on Tuesday, March 18th were issued a dividend of $0.1212 per share. The ex-dividend date of this dividend was Tuesday, March 18th. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.